Abstract: Anti-CD223 antibodies overcome immune suppression in cancer patients. The anti-CD223 antibodies may be generated in an animal by injection of fragments of CD223. Antibodies may be monoclonal antibodies or single chain antibodies or humanized antibodies.
Type:
Grant
Filed:
December 18, 2015
Date of Patent:
September 29, 2020
Assignees:
The Johns Hopkins University, St. Jude's Children's Research Hospital, Inc.
Inventors:
Drew M. Pardoll, Ching-Tai Huang, Jonathan Powell, Charles Drake, Dario A. Vignali, Creg J. Workman
Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
Type:
Grant
Filed:
December 28, 2017
Date of Patent:
September 15, 2020
Assignees:
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., NATIONAL UNIVERSITY OF SINGAPORE
Abstract: The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.
Type:
Grant
Filed:
August 26, 2019
Date of Patent:
September 15, 2020
Assignees:
National University of Singapore, St. Jude Children's Research Hospital, Inc.
Inventors:
Dario Campana, David Shook, Masaru Imamura
Abstract: The invention is directed to a method for improving learning and/or memory (e.g., auditory, visual, somatosensory or motor) in adults and children of an age which is beyond the early critical period for learning, said method comprising inhibiting (i) ecto-5?-nucleotidase (Nt5e, aka CD73) or (ii) A1 adenosine receptor (A1R, aka Adora1) expression or function in the brain. The invention is also directed to a method for treating learning and memory defects and neurological diseases associated with an abnormal auditory, visual, or somatosensory perception by inhibiting Nt5e or A1R expression or function in the brain.
Type:
Grant
Filed:
February 18, 2016
Date of Patent:
June 30, 2020
Assignee:
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
Inventors:
Stanislav S. Zakharenko, Jay A. Blundon
Abstract: A modified effector cell includes a non-reversibly produced vector-encoded anti-GD2-BB-? chimeric receptor for use in disialoganglioside GD2-expressing neoplasia, which is inserted in the cell, to obtain an effector cell that stably produces the anti-GD2-BB-? chimeric receptor, the chimeric receptor having two distinct mutually fused portions, i.e. an intra-cytoplasmic portion and an extra-cytoplasmic portion.
Type:
Grant
Filed:
October 25, 2012
Date of Patent:
May 12, 2020
Assignee:
St. Jude Children's Research Hospital, Inc.
Inventors:
Massimo Dominici, Sara Caldrer, Maria Carlotta Spano, Paolo Paolucci, Marco Bestagno, Dario Campana
Abstract: The invention provides methods for overcoming glucocorticoid resistance of cancers by inhibition of CASP1. Also disclosed are diagnostic methods for determining glucocorticoid resistance potential by measuring expression level or promoter methylation status of CASP1 gene and/or NLRP3 gene.
Type:
Application
Filed:
October 2, 2019
Publication date:
April 2, 2020
Applicant:
St. Jude Children's Research Hospital, Inc.
Inventors:
Steven W. Paugh, William E. Evans, Erik Bonten
Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompansses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
Type:
Grant
Filed:
October 28, 2016
Date of Patent:
January 21, 2020
Assignees:
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., NATIONAL UNIVERSITY OF SINGAPORE
Abstract: The invention is directed to a method for treating the 22q11 deletion syndrome (22q11 DS) and schizophrenia (SCZ) by replenishment of decreased levels of miR-338-3p in thalamic neurons.
Type:
Application
Filed:
September 26, 2019
Publication date:
January 16, 2020
Applicant:
St. Jude Children's Research Hospital, Inc.
Abstract: The invention provides methods for overcoming glucocorticoid resistance of cancers by inhibition of CASP1. Also disclosed are diagnostic methods for determining glucocorticoid resistance potential by measuring expression level or promoter methylation status of CASP1 gene and/or NLRP3 gene.
Type:
Grant
Filed:
September 16, 2014
Date of Patent:
October 29, 2019
Assignee:
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
Inventors:
Steven W. Paugh, William E. Evans, Erik Bonten
Abstract: The invention is directed to a method for treating the 22q11 deletion syndrome (22q11 DS) and schizophrenia (SCZ) by replenishment of decreased levels of miR-338-3p in thalamic neurons.
Type:
Grant
Filed:
June 30, 2016
Date of Patent:
October 15, 2019
Assignee:
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
Abstract: The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.
Type:
Grant
Filed:
May 14, 2015
Date of Patent:
October 1, 2019
Assignees:
National University of Singapore, St. Jude Children's Research Hospital, Inc.
Inventors:
Dario Campana, David Shook, Masaru Imamura
Abstract: The invention is directed to the use of Retinoid X Receptor-gamma (RXR-gamma) agonists and Retinoid X Receptor-alpha (RXR-alpha) antagonists in treatment of cancer.
Type:
Grant
Filed:
October 24, 2014
Date of Patent:
May 14, 2019
Assignee:
St. Jude Children's Research Hospital, Inc.
Abstract: The invention relates to aryl substituted aminomethyl spectinomycin analogs, derivatives thereof, and related compounds, which are useful as anti-bacterial agents; methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating anti-bacterial infections using the compounds and compositions.
Type:
Grant
Filed:
September 29, 2014
Date of Patent:
April 23, 2019
Assignee:
St. Jude Children's Research Hospital, Inc.
Inventors:
Richard E. Lee, Samanthi L. Waidyarachchi, David F. Bruhn, Jiuyu Liu, Zhong Zheng, Jason W. Rosch
Abstract: The invention provides a method for rapid cloning of T-cell receptors (TCRs) (e.g., paired ?? and ?? TCR chains) and B-cell receptors (BCRs) (e.g. paired IgH or IgK or Ig?) from single cells by CDR3 substitution using single cell PCR products and Gibson Assembly techniques and a pre-generated TCR (or BCR) library in an expression vector.
Type:
Application
Filed:
December 2, 2016
Publication date:
February 7, 2019
Applicant:
St. Jude Children's Research Hospital, Inc.
Abstract: The invention is directed to a method for treating the 22q11 deletion syndrome (22q11 DS) and schizophrenia (SCZ) by replenishment of decreased levels of miR-338-3p in thalamic neurons.
Type:
Application
Filed:
June 30, 2016
Publication date:
November 8, 2018
Applicant:
St. Jude Children's Research Hospital, Inc.
Abstract: Compounds for the treatment of bacterial and parasitic infections which are hybrid compounds of compounds having antibacterial or antiparasitic activity and compounds that decrease the absorption of the hybrid compound from the gastrointestinal tract. The compounds are preferably for use against C. difficile infections and comprise a hybrid molecule of an anti-C. difficile compound such as a nitroimidazole and a tetramic acid derivative.
Type:
Grant
Filed:
March 12, 2015
Date of Patent:
July 3, 2018
Assignees:
Board of Regents, The University of Texas System, St. Jude Children's Research Hospital, Inc.
Inventors:
Richard E. Lee, Philip T. Cherian, Julian G. Hurdle, Xiaoqian Wu
Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
Type:
Application
Filed:
December 28, 2017
Publication date:
May 17, 2018
Applicants:
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., NATIONAL UNIVERSITY OF SINGAPORE
Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
Type:
Application
Filed:
December 28, 2017
Publication date:
May 17, 2018
Applicants:
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., NATIONAL UNIVERSITY OF SINGAPORE
Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
Type:
Application
Filed:
December 28, 2017
Publication date:
May 17, 2018
Applicants:
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC, NATIONAL UNIVERSITY OF SINGAPORE
Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
Type:
Application
Filed:
December 28, 2017
Publication date:
May 17, 2018
Applicants:
ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC., NATIONAL UNIVERSITY OF SINGAPORE